4) Emerging and Pharmaceutical-based Agent Threats (EMPATH)
Abstract
The Warfighter requires effective MCMs that prevent or reverse the adverse effects of Pharmaceutical Based Agents (PBAs) and Emerging Chemical Threats (ECTs), while still allowing for the use of FDA approved drugs (e.g. morphine, fentanyl) by Joint Force Medical Staff for their originally intended purposes of pain management and sedation. This portfolio seeks to develop MCMs that are efficacious against a range of toxidromes, are fast-acting, and have a prolonged protective and/or therapeutic benefit to minimize the potential for re-intoxication and maintain Force Lethality.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2024
- Source ID
- 195a6c2cd5e150c735e50c506d805372